Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design.
暂无分享,去创建一个
Ziyaur Rahman | M. Khan | M. Habib | Ziyaur Rahman | A. Zidan | Ahmed S. Zidan | Muhammad J. Habib | Mansoor A. Khan | A. Zidan | Ahmed S Zidan
[1] G. Akman-Demir,et al. Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement? , 2008, Clinical and experimental rheumatology.
[2] D. Rodríguez‐Puyol,et al. Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[3] Zhanju Liu,et al. Current strategies for the treatment of ulcerative colitis. , 2009, Recent patents on inflammation & allergy drug discovery.
[4] K. A. Khan. The concept of dissolution efficiency , 1975, The Journal of pharmacy and pharmacology.
[5] Quantitative determination of amorphous cyclosporine in crystalline cyclosporine samples by Fourier transform infrared spectroscopy. , 2006, Journal of pharmaceutical sciences.
[6] K. Järvinen,et al. In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A. , 2006, International journal of pharmaceutics.
[7] N A Peppas,et al. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). , 2001, Advanced drug delivery reviews.
[8] H. Takeuchi,et al. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[9] M. R. Kumar,et al. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[10] Tao Zhang,et al. Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[11] M. Vert,et al. Preparation and degradation of surfactant-free PLAGA microspheres , 1995 .
[12] Arash Akhavan,et al. Atopic dermatitis: systemic immunosuppressive therapy. , 2008, Seminars in cutaneous medicine and surgery.
[13] T. Higuchi. MECHANISM OF SUSTAINED-ACTION MEDICATION. THEORETICAL ANALYSIS OF RATE OF RELEASE OF SOLID DRUGS DISPERSED IN SOLID MATRICES. , 1963, Journal of pharmaceutical sciences.
[14] N. Yoshimura,et al. Dialysis and renal transplantation as renal replacement therapy for end-stage renal failure, with special reference to the ethical problems of living renal donation , 2001 .
[15] Steven P Schwendeman,et al. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. , 2008, International journal of pharmaceutics.
[16] G. V. Patil,et al. Release modulating hydrophilic matrix systems of losartan potassium: optimization of formulation using statistical experimental design. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[17] R. Jalil,et al. Microencapsulation using poly(L-lactic acid). I: Microcapsule properties affected by the preparative technique. , 1989, Journal of microencapsulation.
[18] R. Plackett,et al. THE DESIGN OF OPTIMUM MULTIFACTORIAL EXPERIMENTS , 1946 .
[19] Mohamed H. El-Shabouri,et al. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. , 2002, International journal of pharmaceutics.
[20] A. Abdul-Fattah,et al. Properties and stability of a liquid crystal form of cyclosporine-the first reported naturally occurring peptide that exists as a thermotropic liquid crystal. , 2003, Journal of pharmaceutical sciences.
[21] S. Chimenti,et al. Efficacy of Short-Term Cyclosporine Treatment to Control Psoriasis-Related Events during Efalizumab Therapy , 2008, Dermatology.
[22] M. Blanco-Prieto,et al. Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides. , 1997, Advanced drug delivery reviews.
[23] R. Venkataramanan,et al. Clinical Pharmacokinetics of Cyclosporin , 1986, Clinical pharmacokinetics.
[24] R. Reithmeier,et al. Differential interaction of human renal P-glycoprotein with various metabolites and analogues of cyclosporin A. , 1995, The American journal of physiology.
[25] Yi Yan Yang,et al. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. , 2001, Biomaterials.
[26] R. Kryscio,et al. Dosing and safety of cyclosporine in patients with severe brain injury. , 2008, Journal of neurosurgery.
[27] Qing Yang,et al. Biodegradable Progesterone Microsphere Delivery System for Osteoporosis Therapy , 2000, Drug development and industrial pharmacy.
[28] A. Fahr. Cyclosporin Clinical Pharmacokinetics , 1993, Clinical pharmacokinetics.
[29] F. Ahmad,et al. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[30] F. Hirayama,et al. Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution. , 1999, Journal of pharmaceutical sciences.
[31] Yi Yan Yang,et al. Effect of preparation conditions on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion method , 2000 .
[32] A. Czogalla,et al. Oral cyclosporine A - the current picture of its liposomal and other delivery systems , 2008, Cellular & Molecular Biology Letters.
[33] P. Emery,et al. Clinical Use of Cyclosporin in Rheumatoid Arthritis , 2012, Drugs.
[34] R. Yousuf,et al. Once-daily tablet formulation and in vitro release evaluation of cefpodoxime using hydroxypropyl methylcellulose: a technical note. , 2006, AAPS PharmSciTech.
[35] C. Chaw,et al. Ciclosporin-loaded poly(lactide) microparticles: Effect of TPGS , 2009, Journal of microencapsulation.
[36] R. Dahlqvist,et al. Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing , 2004, European Journal of Clinical Pharmacology.
[37] S. Davis,et al. The preparation and characterisation of poly(lactide-co-glycolide) microparticles. I: Oil-in-water emulsion solvent evaporation , 1991 .